Financhill
Sell
6

MRNA Quote, Financials, Valuation and Earnings

Last price:
$30.53
Seasonality move :
28.18%
Day range:
$30.70 - $32.42
52-week range:
$30.70 - $170.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.37x
P/B ratio:
1.00x
Volume:
10M
Avg. volume:
11.8M
1-year change:
-64.62%
Market cap:
$11.9B
Revenue:
$6.8B
EPS (TTM):
-$5.82

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MRNA
Moderna
$941.1M -$2.73 -63.53% -79.68% $62.01
BIIB
Biogen
$2.4B $3.36 1.22% 101.89% $221.98
GILD
Gilead Sciences
$7.2B $1.70 -0.47% 49.16% $101.24
JNJ
Johnson & Johnson
$22.4B $2.01 1.33% 97.03% $168.64
LLY
Eli Lilly and
$13.4B $5.07 45.96% 90.83% $979.86
MRK
Merck &
$15.5B $1.67 -0.23% 13.87% $116.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MRNA
Moderna
$30.93 $62.01 $11.9B -- $0.00 0% 2.37x
BIIB
Biogen
$139.39 $221.98 $20.3B 12.59x $0.00 0% 2.12x
GILD
Gilead Sciences
$96.14 $101.24 $119.8B 1,068.22x $0.77 3.2% 4.25x
JNJ
Johnson & Johnson
$156.13 $168.64 $375.9B 26.97x $1.24 3.15% 4.27x
LLY
Eli Lilly and
$865.00 $979.86 $777.9B 73.87x $1.30 0.6% 17.36x
MRK
Merck &
$86.54 $116.67 $218.9B 12.86x $0.81 3.61% 3.43x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MRNA
Moderna
-- -0.029 -- 3.95x
BIIB
Biogen
27.78% 0.011 22.29% 0.68x
GILD
Gilead Sciences
55.72% 0.444 22.27% 0.82x
JNJ
Johnson & Johnson
33.76% 0.843 -- 0.70x
LLY
Eli Lilly and
68.61% 1.194 -- 0.63x
MRK
Merck &
46.15% 0.628 -- 0.88x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MRNA
Moderna
$1.3B -$70M -17.44% -17.44% 1.46% -$1.7B
BIIB
Biogen
$1.8B $496.4M 7.34% 10.52% 20.72% $805.6M
GILD
Gilead Sciences
$6B $3.1B 0.29% 0.64% 15.83% $4.2B
JNJ
Johnson & Johnson
$15.4B $3.6B 13.37% 20.88% 16.17% $5.7B
LLY
Eli Lilly and
$11.1B $5.7B 25.96% 66.4% 41.99% -$458.9M
MRK
Merck &
$11.8B $4.3B 21.98% 29.26% 27.82% $8.5B

Moderna vs. Competitors

  • Which has Higher Returns MRNA or BIIB?

    Biogen has a net margin of 0.7% compared to Moderna's net margin of 15.76%. Moderna's return on equity of -17.44% beat Biogen's return on equity of 10.52%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    BIIB
    Biogen
    74.1% $2.66 $22.7B
  • What do Analysts Say About MRNA or BIIB?

    Moderna has a consensus price target of $62.01, signalling upside risk potential of 100.47%. On the other hand Biogen has an analysts' consensus of $221.98 which suggests that it could grow by 59.25%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    5 15 1
    BIIB
    Biogen
    13 17 0
  • Is MRNA or BIIB More Risky?

    Moderna has a beta of 1.589, which suggesting that the stock is 58.912% more volatile than S&P 500. In comparison Biogen has a beta of -0.082, suggesting its less volatile than the S&P 500 by 108.236%.

  • Which is a Better Dividend Stock MRNA or BIIB?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or BIIB?

    Moderna quarterly revenues are $1.9B, which are smaller than Biogen quarterly revenues of $2.5B. Moderna's net income of $13M is lower than Biogen's net income of $388.5M. Notably, Moderna's price-to-earnings ratio is -- while Biogen's PE ratio is 12.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 2.37x versus 2.12x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    2.37x -- $1.9B $13M
    BIIB
    Biogen
    2.12x 12.59x $2.5B $388.5M
  • Which has Higher Returns MRNA or GILD?

    Gilead Sciences has a net margin of 0.7% compared to Moderna's net margin of 16.61%. Moderna's return on equity of -17.44% beat Gilead Sciences's return on equity of 0.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    GILD
    Gilead Sciences
    79.14% $1.00 $41.6B
  • What do Analysts Say About MRNA or GILD?

    Moderna has a consensus price target of $62.01, signalling upside risk potential of 100.47%. On the other hand Gilead Sciences has an analysts' consensus of $101.24 which suggests that it could grow by 5.3%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    5 15 1
    GILD
    Gilead Sciences
    12 11 0
  • Is MRNA or GILD More Risky?

    Moderna has a beta of 1.589, which suggesting that the stock is 58.912% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.085%.

  • Which is a Better Dividend Stock MRNA or GILD?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.77 per share. Moderna pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MRNA or GILD?

    Moderna quarterly revenues are $1.9B, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Moderna's net income of $13M is lower than Gilead Sciences's net income of $1.3B. Notably, Moderna's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,068.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 2.37x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    2.37x -- $1.9B $13M
    GILD
    Gilead Sciences
    4.25x 1,068.22x $7.5B $1.3B
  • Which has Higher Returns MRNA or JNJ?

    Johnson & Johnson has a net margin of 0.7% compared to Moderna's net margin of 15.24%. Moderna's return on equity of -17.44% beat Johnson & Johnson's return on equity of 20.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    JNJ
    Johnson & Johnson
    68.35% $1.41 $105.9B
  • What do Analysts Say About MRNA or JNJ?

    Moderna has a consensus price target of $62.01, signalling upside risk potential of 100.47%. On the other hand Johnson & Johnson has an analysts' consensus of $168.64 which suggests that it could grow by 8.01%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    5 15 1
    JNJ
    Johnson & Johnson
    7 11 0
  • Is MRNA or JNJ More Risky?

    Moderna has a beta of 1.589, which suggesting that the stock is 58.912% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.520, suggesting its less volatile than the S&P 500 by 48.041%.

  • Which is a Better Dividend Stock MRNA or JNJ?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.15% to investors and pays a quarterly dividend of $1.24 per share. Moderna pays -- of its earnings as a dividend. Johnson & Johnson pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or JNJ?

    Moderna quarterly revenues are $1.9B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Moderna's net income of $13M is lower than Johnson & Johnson's net income of $3.4B. Notably, Moderna's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 26.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 2.37x versus 4.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    2.37x -- $1.9B $13M
    JNJ
    Johnson & Johnson
    4.27x 26.97x $22.5B $3.4B
  • Which has Higher Returns MRNA or LLY?

    Eli Lilly and has a net margin of 0.7% compared to Moderna's net margin of 32.59%. Moderna's return on equity of -17.44% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    LLY
    Eli Lilly and
    82.24% $4.88 $45.4B
  • What do Analysts Say About MRNA or LLY?

    Moderna has a consensus price target of $62.01, signalling upside risk potential of 100.47%. On the other hand Eli Lilly and has an analysts' consensus of $979.86 which suggests that it could grow by 13.28%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    5 15 1
    LLY
    Eli Lilly and
    15 6 0
  • Is MRNA or LLY More Risky?

    Moderna has a beta of 1.589, which suggesting that the stock is 58.912% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.369%.

  • Which is a Better Dividend Stock MRNA or LLY?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.6% to investors and pays a quarterly dividend of $1.30 per share. Moderna pays -- of its earnings as a dividend. Eli Lilly and pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or LLY?

    Moderna quarterly revenues are $1.9B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Moderna's net income of $13M is lower than Eli Lilly and's net income of $4.4B. Notably, Moderna's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 73.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 2.37x versus 17.36x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    2.37x -- $1.9B $13M
    LLY
    Eli Lilly and
    17.36x 73.87x $13.5B $4.4B
  • Which has Higher Returns MRNA or MRK?

    Merck & has a net margin of 0.7% compared to Moderna's net margin of 23.96%. Moderna's return on equity of -17.44% beat Merck &'s return on equity of 29.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRNA
    Moderna
    72.29% $0.03 $11.9B
    MRK
    Merck &
    75.5% $1.48 $82.7B
  • What do Analysts Say About MRNA or MRK?

    Moderna has a consensus price target of $62.01, signalling upside risk potential of 100.47%. On the other hand Merck & has an analysts' consensus of $116.67 which suggests that it could grow by 34.82%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRNA
    Moderna
    5 15 1
    MRK
    Merck &
    13 9 0
  • Is MRNA or MRK More Risky?

    Moderna has a beta of 1.589, which suggesting that the stock is 58.912% more volatile than S&P 500. In comparison Merck & has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.682%.

  • Which is a Better Dividend Stock MRNA or MRK?

    Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.61% to investors and pays a quarterly dividend of $0.81 per share. Moderna pays -- of its earnings as a dividend. Merck & pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRNA or MRK?

    Moderna quarterly revenues are $1.9B, which are smaller than Merck & quarterly revenues of $15.6B. Moderna's net income of $13M is lower than Merck &'s net income of $3.7B. Notably, Moderna's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 2.37x versus 3.43x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRNA
    Moderna
    2.37x -- $1.9B $13M
    MRK
    Merck &
    3.43x 12.86x $15.6B $3.7B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock